Omodenbamab immunoglobulin, designated with the code 2241724-48-9, encompasses a novel monoclonal protein currently experiencing investigation addressing its anticipated therapeutic purposes, specifically targeting adenylyl cyclase type 2. Experts are: have been exploring its process of operation and determining its power concerning various: multip